

Provided by:



CCEB Seminar Lecture Series 2023-2024 2024

CCEB Seminar Lecture Series 2023-2024 - 5/1/2024 | Alonso Carrasco-Labra | Advancing Trustworthy Clinical Practice Guidelines: The Rise of Living, AI-Enhanced Evidence-Based Recommendations

May 1, 2024

9:00 AM - 10:00 AM

Target Audience

This program has been designed for ALL SPECIALTIES

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss how to select appropriate targets for intervention to improve public health
- 1 Review statistical techniques (e.g. logistic regression) with appropriate understanding of limitations and assumptions made
- 3 Describe appropriate disease management goals (eg. Blood pressure target) for their individual patients

Session Educational Objectives

After completing this educational activity, participants should be able to:

- 1 Discuss the principles for creating and disseminating trustworthy evidence-based clinical practice guidelines.
- 2 Discuss the concept of living guidelines and living evidence synthesis to optimize the delivery of continuously updated clinical and policy recommendations.

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is not approved for nursing contact hours

Pharmacists: This activity is approved for 1.00 contact hours

UAN Number: JA0000324-0000-24-017-L04-P

PAs: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 credits for completing this activity.

Acknowledgement of Commercial Support*

None

For more information, please contact
Mark Burnett, Mae Phelps
(215) 898-1708, No phone on file

Mark.Burnett@Pennmedicine.upenn.edu, emae@upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Robert Gross, MD	Other Planning Committee Member	Independent Contractor (included contracted research)-Pfizer, Inc. - 03/21/2024
Michael Z David, MD, MS, PhD	Co-Director	Consulting Fee-Glaxo Smith Kline (Relationship has ended) Grant or research support-Glaxo Smith Kline (Relationship has ended) Consulting Fee-Johnson & Johnson (Relationship has ended) Grant or research support-Contrafect (Relationship has ended) - 08/29/2023
David Margolis, MD	Other Planning Committee Member	Consulting Fee-Pfizer, Inc. (Relationship has ended) Consulting Fee-Comanche Biopharma Consulting Fee-Insmed Consulting Fee-Everest (Relationship has ended) Consulting Fee-Johnson & Johnson Grant or research support-Bausch Health a Valeant Pharmaceuticals Co. Grant or research support-Pfizer, Inc. (Relationship has ended) - 08/30/2023
Mary Putt II, PhD, ScD	Other Planning Committee Member	Other: Support of Statistical Issues in Annual Clinical Trials Conference-Merck & Co Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Eli Lilly Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Novartis / Amgen Stocks or stock options, excluding diversified mutual funds of

		a publicly traded company-Roche Pharmaceuticals - 03/18/2024
Alexis Ogdie, MD	Other Planning Committee Member	Consulting Fee-Pfizer, Inc. Grant or research support-Janssen Pharmaceuticals (J&J) Consulting Fee-CorEvidas Honoraria-Kopa/Twill, Gilead Grant or research support-AbbVie, Inc. Grant or research support-Novartis / Amgen Grant or research support-Pfizer, Inc. Consulting Fee-Janssen Pharmaceuticals (J&J) Consulting Fee-Glaxo Smith Kline Consulting Fee-UCB Consulting Fee-Bristol-Myers Squibb Consulting Fee-Novartis / Amgen Consulting Fee-AbbVie, Inc. - 09/20/2023
Ricardo Castillo-Neyra, DVM	Co-Director	Nothing to disclose - 08/07/2023
Sean Hennessy, PharmD	Pharmacy Planner	Consulting Fee-Intercept Pharmaceuticals (Relationship has ended) Consulting Fee-Urovant Sciences (Relationship has ended) Consulting Fee-Covis Pharma GmbH (Relationship has ended) Consulting Fee-Astra Zeneca Pharmaceuticals Consulting Fee-Novo Nordisk Consulting Fee-Glaxo Smith Kline Consulting Fee-Eli Lilly Consulting Fee-Provention Bio, Inc (Relationship has ended) Consulting Fee-Bluebird Bio, Inc (Relationship has ended) Consulting Fee-Amylyx Pharmaceuticals Inc (Relationship has ended) Consulting Fee-Ipsen (Relationship has ended) Consulting Fee-i2o (Relationship has ended) - 09/21/2023
Alonso Carrasco-Labra, MSc, PhD	Faculty	Nothing to disclose - 04/12/2024
Ellen C Caniglia	Co-Director	Nothing to disclose - 08/07/2023

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected